Cargando…

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells

BACKGROUND: Cancer stem cells (CSCs) contribute towards disease aggressiveness and drug resistance. Specific identification of CSC maintenance genes and targeting can improve the efficiency of currently available treatment modalities. Pancreatic differentiation 2 (PD2) has a major role in the self-r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaz, A P, Ponnusamy, M P, Rachagani, S, Dey, P, Ganti, A K, Batra, S K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119968/ https://www.ncbi.nlm.nih.gov/pubmed/25003666 http://dx.doi.org/10.1038/bjc.2014.152

Ejemplares similares

Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation
por: Souchek, J J, et al.
Publicado: (2014)

Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells
por: Sahu, R P, et al.
Publicado: (2009)

Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells
por: Moniaux, N, et al.
Publicado: (2007)

PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer
por: Su, Y, et al.
Publicado: (2010)

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma
por: Beckermann, B M, et al.
Publicado: (2008)

Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells
por: Barkeer, Srikanth, et al.
Publicado: (2018)

PD2/Paf1 depletion in pancreatic acinar cells promotes acinar-to-ductal metaplasia
por: Dey, Parama, et al.
Publicado: (2014)

Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
por: Schulz, P, et al.
Publicado: (2008)

The x(c)(−) cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
por: Lo, M, et al.
Publicado: (2008)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer
por: Hasegawa, S, et al.
Publicado: (2014)

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
por: Liles, J S, et al.
Publicado: (2011)

CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
por: Singh, S, et al.
Publicado: (2010)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
por: Bocci, G, et al.
Publicado: (2005)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
por: Pothula, Srinivasa P, et al.
Publicado: (2016)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Clinical importance of B7-H3 expression in human pancreatic cancer
por: Yamato, I, et al.
Publicado: (2009)

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
por: Bapiro, T E, et al.
Publicado: (2014)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma
por: Karakhanova, S, et al.
Publicado: (2015)

HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer
por: Veite-Schmahl, Michelle J, et al.
Publicado: (2017)

ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer
por: Watanabe, T, et al.
Publicado: (2015)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
por: Patel, Girijesh Kumar, et al.
Publicado: (2017)

Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation
por: Cheng, G, et al.
Publicado: (2014)

FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer
por: Nomura, S, et al.
Publicado: (2008)

Adenovirus-mediated interferon α gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer
por: Ohashi, M, et al.
Publicado: (2005)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
por: Imai, K, et al.
Publicado: (2011)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
por: Cao, P, et al.
Publicado: (2009)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation
por: Hennig, R, et al.
Publicado: (2008)

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
por: Alhasan, Sari F, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_50frui6dm8dehb1eokelo67lb5